Respiratory failure & ventilation
Inhaled Sedation in Acute Respiratory Distress Syndrome: The SESAR Randomized Clinical Trial
Authors' conclusion
Among patients with moderate to severe ARDS, inhaled sedation with sevoflurane resulted in fewer ventilator-free days at day 28 and lower 90-day survival than sedation with propofol.
Study context
- Population
- Adults with early moderate to severe ARDS (PaO2/FiO2 <150 mm Hg with PEEP ≥8 cm H2O), 37 French ICUs
- Participants
- 687 adults
- Comparison
- Inhaled sevoflurane vs IV propofol sedation for up to 7 days
- Sevofluranen = 346
- Propofoln = 341reference
- Primary endpoint
- Number of ventilator-free days
- Follow-up
- 28 days
Methodological detailsphase 3, open-label, assessor-blinded, multicentre, May 2020 to October 2023, 90-day follow-up, 37 French ICUs
- Phase 3
- Open-label
- Assessor-blinded
- Multicentre
- May 2020 to October 2023, 90-day follow-up
- 37 French ICUs
Primary result
As reported in the abstract
Ventilator-free days through day 28 · day 28
Sevoflurane
0.0
IQR 0.0–11.9 · days
Propofol
0.0
IQR 0.0–18.7 · days
Each group vs propofolMedian difference (95% CI)
Sevoflurane
−2.1(−3.6 to −0.7)
Each group vs propofolStandardized hazard ratio (95% CI)
Sevoflurane
0.76(0.50–0.97)
Secondary outcomes
| Outcome | Sevoflurane | Propofol | Estimate | |
|---|---|---|---|---|
| 90-day survival (key secondary end point) | 47.1% | 55.7% | HR for death 1.31 (95% CI 1.05–1.62) | |
| 7-day mortality · up to 7 days | 19.4% | 13.5% | RR 1.44 (95% CI 1.02–2.03) | |
| 0.512Ratio (log scale) |
| Outcome | Median difference (95% CI) | |
|---|---|---|
| ICU-free days through day 28 | −2.5 (−3.7 to −1.4) | |
| −4−202Difference (linear scale) |
Original publication
Inhaled Sedation in Acute Respiratory Distress Syndrome: The SESAR Randomized Clinical Trial. JAMA. Published 13 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →